Alternative Models of Comorbidity: A Framework for the Interpretation of Epidemiological Association Studies  by Schmitt, Jochen & Weidinger, Stephan
work of Matsui et al. (2014) now allows
a rather compelling picture to fall into
place.
The learning points
For clinicians, this paper shows that H1
blockers may be useful in AD, but only
as an ‘‘add on’’, with close monitoring of
responses. The second-generation anti-
histamines would be more useful than
first-generation antihistamines, which
are associated with a number of unde-
sired effects, most importantly changes
in REM sleep patterns and reduced
cognitive function (Church et al., 2010).
This paper also shows that we need
better clinical trials in diseases such as
AD, which have heterogeneous popula-
tion bases. Individual treatment responses
may be quite important. For investiga-
tors, the message is simple: apparently
simple minor features of a disease may
lead to novel findings; congratulations
go to Matsui et al. (2014).
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Clinical Implications
 A novel pathomechanism is proposed for the attenuated sweating found
in patients with atopic dermatitis (AD).
 Sweating can be inhibited via H1-receptor activation.
 The use of H1 blockers is a novel approach to treating some patients
with AD.
Alternative Models of Comorbidity: A
Framework for the Interpretation of
Epidemiological Association Studies
Jochen Schmitt1 and Stephan Weidinger2
Relationships between chronic diseases have emerged as major clinical, public
health and research issues. Consequently, clinical and epidemiological research
on comorbidities of skin diseases is increasingly recognized as an important tool
to understand their etiologies more fully and to capture their morbidities and
burdens. In this issue, Flohr and colleagues report a cross-sectional analysis on the
complex associations among atopic dermatitis, filaggrin loss-of-function muta-
tions, skin barrier function, and food sensitization in exclusively breastfed infants.
When interpreting this and other association studies, various alternative models of
comorbidity should be considered as suggested by Neale and Kendler.
Journal of Investigative Dermatology (2014) 134, 303–307. doi:10.1038/jid.2013.527
Comorbidity studies in dermatology
With increasing life expectancy, the
simultaneous presence of multiple patho-
logical conditions in the form of comor-
bidity and multimorbidity has become
common. The term ‘‘comorbidity’’ was
coined initially to describe the occur-
rence of an independent medical con-
dition in addition to an index disease
(Feinstein, 1970). In a broader under-
standing, the term has been used inter-
changeably with ‘‘multimorbidity’’ to
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describe the concurrent presence of two
or more medically diagnosed diseases
or even subclinical outcomes, whether
causally related or not (Fried et al.,
2014).
AD is a common chronic relapsing
inflammatory skin disorder that affects
up to 20% of children and 3–5% of
adults. Intractable itching associated
with poor sleep and visible physical stig-
mata can lead to substantial problems in
everyday life for affected patients and
their families (Williams, 2005). Based
on the frequent co-occurrence of atopic
diseases and the established association
of early AD with later asthma and
rhinitis, the concept of the ‘‘atopic
march’’ has been developed. Sensu
stricto, the ‘‘march’’ implies a longitudi-
nal progression of individuals through a
predictable and sequential/overlapping
series of phenotypes, from AD, food
allergy, through asthma, and subse-
quently allergic rhinitis. However, this
concept has been challenged by cohort
studies (Flohr et al., 2004; Williams and
Flohr, 2006), and the postulated tempo-
ral and causal relationship between
early AD and subsequent asthma de-
serves further investigation.
Recently, the association of AD with
cancer (Wang and Diepgen, 2006), with
other inflammatory disorders (Deckert
et al., 2013), and with mental disorders
(Schmitt et al., 2009; Romanos et al.,
2011) has gained increasing interest. In
this issue, Flohr et al. (2014) report a
cross-sectional analysis on the com-
plex association between AD, FLG
mutations, skin barrier function, and
food sensitization (FS) in exclusively
breastfed infants. We will discuss the
implications of this study in more detail
below.
Comorbidity is not only a hot topic in
AD, but also in other important areas of
dermatological research. The relation-
ships between psoriasis and cardiovas-
cular risk factors and cardiovascular
disease on one hand and with psychia-
tric disorders on the other hand are
under intensive investigation (Nijsten
and Wakkee, 2009).
Two major objectives appear to sti-
mulate comorbidity studies:
1. To investigate the etiology of disease.
Understanding the underlying biolo-
gical mechanisms of co-occurrence
of diseases offers a key to under-
standing disease pathobiology. Even-
tually, this may lead to preventive or
curative interventions.
2. To capture the whole spectrum of
morbidity and burden of disease.
This is important, not only from the
public health perspective, but also
for individualized, patient-oriented,
interdisciplinary methods of care.
These objectives identify co-occur-
rence of disorders as an important area
for experimental, clinical, epidemiologi-
cal, and methodological investigation,
and they explain why comorbidity stu-
dies have gained interest in dermato-
logical research.
However, the interpretations of
comorbidity studies are not straight for-
ward, as different models of disease
associations, as well as sources of bias
must be considered. Neale and Kendler
(1995) provided a comprehensive set of
possible comorbidity models that offer
a framework for the interpretation of
epidemiological association studies.
We believe that this framework may
be of considerable value for interpreting
comorbidity studies in dermatology.
Before introducing this framework, we
will summarize the main findings by
Flohr et al. (2014) in this issue and then
apply the framework to their study.
Key study characteristics and findings
from Flohr et al.
The study included 619 exclusively
breastfed infants (age 3 months), that
were recruited from the general popula-
tion by advertisements for an interven-
tional trial to prevent food allergy.
Children were examined for AD, disease
severity was determined by means of
the Scoring Atopic Dermatitis
(SCORAD) index, transepidermal water
loss (TEWL) was measured as an indi-
cator of skin barrier function, the six
most common FLG mutations were
genotyped, and skin prick testing was
performed for six common allergenic
foods. Approximately 25% of the chil-
dren (154/619) were diagnosed as hav-
ing AD, most of whom (86%; n¼132)
were classified as having mild AD
(SCORADo20). Twelve percent of the
children (n¼ 75) carried at least one
FLG mutation, 5.5% (n¼ 34) were sen-
sitive to at least one of the six study
foods. As expected, AD was associated
with higher prevalence of FLG muta-
tions (37/154 children with AD; 24%)
and with higher median TEWL, indicat-
ing impaired skin barrier function. AD
was associated with FS, with moderate-
to-severe AD being associated with FS
more strongly than mild AD. How-
ever, the reported association between
AD severity and FS was based on low
numbers (nine comorbid participants
with moderate-to-severe AD). FLG
mutations were not significantly related
to FS (odds ratio 1.21). TEWL was
associated with FS and remained an
independent determinant, after adjusting
for AD presence and FLG mutation
status.
Framework for interpreting comorbidity
studies
The underlying assumption of the Neale
and Kendler (1995) models is that there
is a continuous liability distribution of
multifactorial causes for a disorder. The
disorder manifests in an individual if a
defined threshold in that liability
distribution is reached. This so-called
Clinical Implications
 Associations among atopic dermatitis (AD), filaggrin loss-of-function(FLG)
mutations, skin barrier function, and food sensitivities do not yet provide a
compelling, unified model for atopic disease.
 The study by Flohr et al. (2014) suggests that a defective skin barrier is
related to both AD and food sensitization, but that this effect is
independent from FLG genotype. Thus, stabilization of skin barrier
function, e.g., through early emollient use, might prevent both traits
independently from the individual molecular makeup, supporting the
need for fresh prevention trials aimed at skin barrier enhancement.
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Table 1. Description of the Neale and Kendler (1995) models of comorbidity and application to the study by Flohr
et al. (2014) on the association between atopic dermatitis (AD) and food sensitization (FS)
Name of model Description
Application to findings by Flohr et al. (2004) on the
comorbidity between AD and FS
Artificial sources of comorbidity
Chance Comorbidity is due to chance. There was significantly greater comorbidity between AD and
FS than would be expected by chance (Pp0.001).
- Model rejected.
Sampling bias Comorbid individuals are more likely to participate in study
than individuals with only one single disease. Clinical
samples and hospital studies are prone to sampling bias.
Participants were recruited from the general population
through advertising for an interventional trial for food allergy
prevention.
- Children at increased risk for food allergy and atopic
disorders may be overrepresented. This possible bias unlikely
explains the observed comorbidity.- Model rejected.
Population
stratification
If two disorders have non-overlapping sets of risk factors, but
these risk factors both are more common in certain strata of
the population, then significant comorbidity may be
observed. Twin studies are prone to population stratification.




Alternate forms Comorbid conditions are different (alternate) manifestations
of the same disorder. This model implies that comorbid cases
are no different in mean liability than those who have only
one of the disorders.
AD and food sensitization/food allergy differ in the
immunological mechanisms and other major aspects of
patho-etiology. Flohr et al. (2004) found FLG mutations to be




Excess comorbidity occurs because some cases of one
disorder are epiphenomena (phenocopies) of the second
disorder, and/or vice versa, although both disorders have
unrelated liabilities.
It has been observed previously (Flohr et al., 2004) that those
with more severe AD are also more likely to be sensitized. It
has been speculated, that atopy (allergic sensitization) might
be an easily measurable epiphenomena of AD that does not
necessarily have an important causative role (Williams and
Flohr, 2006). The findings by Flohr et al. (2014) allow the
interpretation that FS is an epiphenomenon of more severe
AD without related liabilities between both disorders.
- Model not rejected.
Extreme
multiformity
Similar to random multiformity, but phenocopies of the
second disorder arise only at the extreme of the distribution
of liability of the other disorder, i.e., the most severely
affected persons.
Flohr et al. (2014) report that the prevalence of FS is also
increased in children with mild AD.
-Model rejected. (Assuming the SCORAD is an adequate




Two disorders are entirely independent. The comorbid
disorder is a third independent dimension, unrelated to
either disorder occurring alone.
The study by Flohr et al. (2014) does neither confirm nor
reject the hypothesis that AD plus (with) FS constitutes a
distinct entity or a syndrome.





Both conditions share genetic and/or environmental risk
factors. Common underlying risk factors explain excess
comorbidity.
Flohr et al. (2014) found FLG mutations to be associated with
AD, but not with FS. Other genetic analyses that may
confirm correlated underlying susceptibility for AD and FS
have not been reported. AD and FS might share
environmental risk factors (e.g., those involved in the
hygiene hypothesis), but this was beyond the scope of the
study by Flohr et al. (2014). In addition to not yet identified
genetic factors, factors of the physical environment might be
a possible common risk factor for both AD and FS given that
Flohr et al. (2004) found an association between TEWL and
FS when adjusting for AD.
- Model not rejected.
Reciprocal
causation
Both disorders cause each other. Cross-sectional studies are unsuitable to study causation.
Therefore, the study presented by Flohr et al. (2014) can
neither confirm nor reject the hypothesis that AD causes FS
or vice versa. Based on our current understanding of the
pathophysiology of FS, AD does not qualify as a potential
cause.
- Reciprocal causation rejected.
Table 1 Continued on following page
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‘‘continuous liability threshold’’ model
applies to AD, food allergy, and other
multifactorial disorders. Neale and
Kendler (1995) specified different
alternative comorbidity models: Three
models describe artificial sources of
comorbidity, four ‘‘true’’ but non-
causal models of comorbidity (i.e.,
alternate forms, different multiformity
models, three independent disorders
model), and three causal models of
comorbidity (i.e., correlated liabilities,
causal model, and reciprocal causation).
Table 1 provides a description of the
comorbidity models and several argu-
ments about whether models are in
accordance with the findings of Flohr
et al. (2014).
Potential models for an association
between AD and allergic sensitization to
foods
Based on the report by Flohr et al. (2014),
all three models describing artificial
sources of comorbidity can be rejected.
Children at increased risk for food allergy
and atopic disorders may be overrepre-
sented, but this potential source of
sampling bias cannot fully explain the
observed comorbidity between AD and
FS. The observation that FLG mutations
were associated with AD, but not with FS,
leads to the rejection of the alternate forms
model, i.e., that AD and FS are alternate
manifestations of one underlying disorder.
One possible model that explains the
observed comorbidity between AD and
FS is random multiformity. This term
means that excess comorbidity occurs
because some cases of one disorder are
epiphenomena (phenocopies) of the sec-
ond disorder, although both disorders
have unrelated liabilities. It has been
speculated previously that atopy (allergic
sensitization) is an ‘‘easy to measure’’
epiphenomenon of AD, one that does
not necessarily have a causative role
(Flohr et al., 2004; Williams and Flohr,
2006). The findings of the present study
(Flohr et al., 2014) do not exclude the
hypothesis that FS is an epiphenomenon
of more severe AD without related
liabilities between both disorders. The
three independent disorders model, i.e.,
that the comorbid state ‘‘AD plus FS’’
constitutes a distinct entity or a syndrome
as it has also been suggested for the
complex endophenotype ADþ asthma
in the context of FLG studies (Rodriguez
et al., 2009) cannot be excluded, based
on the presented study.
Although cross-sectional analyses are
generally not suitable to draw conclu-
sions about causality, the findings by
Flohr et al. (2014) offer several useful
findings for speculations about the three
different causal models of comorbidity as
introduced by Neale and Kendler (1995).
As discussed by the authors, the corre-
lated liabilities/risk factors model, i.e.,
that AD and FS share genetic and/or envi-
ronmental risk factors, offers one possible
interpretation of the study findings. In
addition to yet unknown genetic factors,
factors of the physical environment
and/or factors involved in the hygiene
hypothesis might be common risk factors
for both AD and FS given that Flohr et al.
(2014) observed a significant association
between TEWL and FS when adjusting for
AD. Alternatively, the causal model
might apply. It is well known that food
allergy may, especially in small children,
trigger AD flares. Therefore, it is possible
that all or some of the nine children with
more severe AD (SCORAD 420) and FS
in the sample of Flohr et al. (2014)
actually have food allergies that trigger
AD. If we consider trigger factors as
causes of AD, then FS might be a cause
of AD. For more details on the models of
comorbidity and their application to the
study by Flohr et al. (2014), please refer
to Table 1.
Questions for future research
Research is necessary to identify the
most appropriate model of comorbidity
between AD and FS. Follow-up of the
cohort of exclusively breastfed children
and results of the embedded prevention
trial (Flohr et al., 2014) are expected
to add significantly to our understanding
of the mechanisms underlying the
observed co-occurrence between AD
and FS. Molecular research is nece-
ssary to determine whether AD and FS
share underlying risk factors, e.g.,
intermediate molecular mechanisms of
inflammation (‘‘subclinical traits’’) of
relevance across traditional diseases
entities, what proportion of excess
comorbidity is caused by FS-triggered
(caused) AD, and whether FS is (only) an
epiphenomenon of AD. Only with this
information can the most appropriate
model of comorbidity-targeted preven-
tion and care strategies be developed.
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IL-17: A Key Player in the P. acnes
Inflammatory Cascade?
Diane M. Thiboutot1, Alison M. Layton2 and E. Anne Eady2
Recent advances in our understanding of inflammatory skin diseases now afford
an opportunity to delve deeper into microbial/host interactions in acne. Agak
et al. report that Propionibacterium acnes induces IL-17 expression in peripheral
blood mononuclear cells and present new evidence that IL-17þ cells are found in
the perifollicular infiltrate of comedones. Additional studies are needed to assess
the clinical relevance of IL-17 in acne.
Journal of Investigative Dermatology (2014) 134, 307–310. doi:10.1038/jid.2013.400
Plewig and Kligman (2000) wrote that
‘‘Sebum is the fuel of the acne flame’’.
The question is ‘‘How did the fire get
started?’’.
In this issue, Agak et al. (2014)
present a series of experiments that sup-
port a role for IL-17 in the pathogenesis
of acne. They demonstrate that Propi-
onibacterium acnes induces IL-17
expression in human peripheral blood
mononuclear cells (PBMCs) from
healthy individuals in vitro and that
supernatants from cultures of P. acnes
incubated with PBMCs induce naive
CD4þCD45TAþ T cells to differen-
tiate into Th17 cells (expressing Th17,
RORa, and RORc) and Th1 cells (expre-
ssing IFNg). By using a panel of neutra-
lizing antibodies, they determined that
IL-1b, IL-6, and transforming growth
factor-b (TGFb) regulate P. acnes–
induced IL-17 responses as they do in
other systems. Furthermore, the authors
suggest that the clinical relevance for
these findings is supported by the identi-
fication of IL-17þ cells in perifollicular
infiltrates in biopsies of typical closed
comedone-type acne lesions. Before
concluding that these findings are rele-
vant in the pathogenesis of acne, links
need to be made between the in vitro
and in vivo data. For example, is
See related article on pg 366
P. acnes present universally in follicles
surrounded by an infiltrate containing
IL-17-positive cells and what type of
cells are they? In addition to providing
potential insight into acne pathogenesis,
these data raise questions regarding the
multiplicity of mechanisms by which
P. acnes interacts with immune cells
in vivo, the sequence of events that
initiates and terminates inflammatory
responses in acne and the possible role
of IL-17. Furthermore, demonstration of
the ability of all trans retinoic acid
(ATRA) and vitamin D to suppress
P. acnes–induced generation of Th17
cells suggests a potential new mecha-
nism of action whereby retinoids
and vitamin D might modulate acne
inflammation physiologically or even
pharmacologically.
How does P. acnes wage war in acne?
P. acnes is a commensal organism that
colonizes the pilosebaceous follicles of
people with and without acne. Although
not a classical pathogen, P. acnes have
the capacity to contribute to the genesis
of inflammatory acne via multiple path-
ways (Table 1). Several in vitro studies
demonstrate that P. acnes whole cells
or cell fractions stimulate cytokine
and matrix metalloproteinase release
from immune cells, keratinocytes, and
sebocytes (Kim et al., 2002; Liu et al.,
2005; Nagy et al., 2006; Lee et al.,
2010) (Figure 1a and b).
The mechanism by which P. acnes
exerts its effects on these cells in vivo is
unknown, perhaps via direct contact,
secreted factors, or secondary events
(Table 1). P. acnes resides mainly in
the microaerophilc deeper portions of
healthy follicles where it comes in con-
tact with follicular keratinocytes and
cells within the proximal region of the
sebaceous duct. Within comedones, it
multiplies within the sebum-filled lacu-
nae that form inside of the cornified
plugs. It can be envisioned that P. acnes
whole cells, cell fragments, and/or
secreted factors may exert proinflamma-
tory effects on follicular keratinocytes.
P. acnes comes in direct contact with
the cells within the dermis following
follicular rupture, a late finding in the
development of inflammatory acne
lesions (Plewig and Kligman, 2000).
Soluble factors, however, may escape
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